One patient had a history of nonsevere anaphylaxis and was desensitized having a six-step protocol (Table ?(Table2)2) despite having bad results of SPT (by neat vaccine) and intradermal screening (IDT) (with 1/1,000, 1/100 dilutions)

One patient had a history of nonsevere anaphylaxis and was desensitized having a six-step protocol (Table ?(Table2)2) despite having bad results of SPT (by neat vaccine) and intradermal screening (IDT) (with 1/1,000, 1/100 dilutions). immediate-type ( 4 h) HSR to (group A1 for CoronaVac and group B1 for Pfizer-BioNTech). Equivalent number of subjects who did not show HSR to two doses of either CoronaVac or Pfizer-BioNTech was recruited into the study as control organizations (group A2 for CoronaVac and group B2 for Pfizer-BioNTech). The autologous serum pores and skin test (ASST) was performed on individual and control organizations. Later on, the demographic, medical, and laboratory features were compared between organizations. Results A total number of 27 individuals were included in the study. Subjects with chronic spontaneous urticaria (CSU) were more frequent in group B1 than in group B2 (and Mann-Whitney U checks were used where appropriate. The frequencies of categorical variables were compared using the 2 and Fischer’s precise tests. When more than 20% of cells have expected frequencies 5, Fischer’s precise test or otherwise the 2 2 test was used. ideals 0.05 were considered significant. All statistical analyses were carried out by Statistical Package for the Sociable Sciences version 24.0 (SPSS Inc., Chicago, IL, USA), IDAX and graphs were generated using GraphPad Prism version 8.4.3 software (GraphPad Software Inc., San Diego, CA, USA). Results The Demographic and Clinical Characteristics of Individuals Twenty-seven individuals were included in the study. Netupitant Netupitant Thirteen out of them experienced a history of HSR to CoronaVac and 14 subjects to Pfizer-BioNTech. The mean age groups for them were 34.38 7.8 and 37.28 11.97, respectively. The number of female subjects and history of immediate type HSRs were higher in HSRs to CoronaVac (value OR (CI%)(%)?Females12 (92.3)6 (42.9) 0.009 16 (1.607C159.310)a ?Males1 (7.7)8 (57.1)Body mass index22.1 (21.1C24.7)26.6 (23.5C31.4) 0.05Smokers, (%)6 (50)6 (42.9) 0.05Alcohol users, (%)0 (0)0 (0) 0.05Median reaction time after vaccination, min10 Netupitant (1.5C30)180 (8.75C510) 0.05Reaction to which dose, (%)?1st dose10 (77)12 (85.7) 0.05?Second dose3 (23)2 (14.3) 0.05History of the reaction type, (%)?Urticaria1 (15.4)7 (50) 0.021 12 (1.211C118.889)a ?Angioedema2 (15.4)0 (0) 0.05?Urticaria/angioedema1 (7.7)1 (7.1) 0.05?Anaphylaxis9 (69.2)6 (42.9) 0.05Patients according to the reaction time, (%)?0C4 h13 (100)9 (64.3) 0.025 1.556 (1.053C2.299)a ?4C24 h0 (0)5 (35.7)Individuals according to the severity of the reaction, (%)?Nonsevere reaction4 (30.8)8 (57.1) 0.05?Severe reaction (anaphylaxis)9 (69.2)6 (42.9) 0.05After vaccination, patients showing anaphylaxis (of N), (%)?Nonsevere1 (11.2)2 (33.3) 0.05?Severe8 (88.9)4 (66.7) 0.05Patients with a history of reactions to other vaccines, (%)1 (7.7)0 (0) 0.05Patients with latex level of sensitivity,* (%)0 (0)0 (0)? Open in a separate window Parametric ideals given as mean SD and nonparametric values given as median (IQR 25C75). IQR, interquartile range. aFischer’s precise test used. *Those having a clinically relevant hypersensitivity determined by the skin prick test or specific IgE. Two individuals were desensitized to the second dose of CoronaVac. One individual had a history of nonsevere anaphylaxis and was desensitized having a six-step protocol (Table ?(Table2)2) despite having bad results of SPT (by neat vaccine) and intradermal screening (IDT) (with 1/1,000, 1/100 dilutions). Bronchospasm without hypoxemia ( 90%) inside a min following a last step occurred, but it relieved with inhaler salbutamol (4 puffs) and methylprednisolone (40 mg) treatment, and no HSR reoccurred later on. The other subject had a history of urticaria/angioedema in the 15th min and was desensitized to CoronaVac with the same protocol (Table ?(Table2).2). However, SPT having a neat vaccine resulted positive with this patient and comparably bad in 5 healthy subjects (Fig. ?(Fig.1).1). One min after the last step, the patient experienced a severe itching on her legs. However, it resolved with 45.5 mg pheniramine, and no HSR reoccurred later. Open in a separate windows Fig. 1 a, b Pores and skin prick test results in the patient and one of the 5 control subjects. Table 2 CoronaVac desensitization protocol 0.05). A higher number of individuals experienced allergic comorbidities in group A1 than in group A2 (value OR (CI%)(%)?Females12 (92.3)10 (76.9) 0.05?Males1 (7.7)3 (23.1) 0.05Body mass index22.1 (21.1C24.7)25.53 (22.18C26) 0.05Smokers, (%)2 (15.4)4 (30.8) 0.05Alcohol users, (%)0 (0)0 (0)?Individuals with allergic comorbidity, (%)11 (84.6)4 (30.8) 0.005 0.081 (0.012C0.547)a ?AR*8 (61.5)4 (30.8) 0.05?Allergic asthma4 (30.8)1 (7.7) 0.05?HSR to food2 (15.4)0 (0) 0.05?HSR to drug6 (46.2)0 (0) 0.007 0.350 (0.193C0.636)b ?Allergic contact dermatitis1 (7.7)0 (0) 0.05?CSU6 (46.2)0 (0) 0.007 0.350 (0.193C0.636)b ?Bee venom allergy1 (7.7)0 (0) 0.05Patients with.